Renaissance Technologies LLC Lowers Stake in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Renaissance Technologies LLC lessened its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,881,238 shares of the company's stock after selling 106,000 shares during the period. Renaissance Technologies LLC owned approximately 0.76% of GoodRx worth $13,398,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. National Bank of Canada FI increased its position in shares of GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares during the last quarter. Gagnon Securities LLC increased its holdings in GoodRx by 9.9% in the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company's stock valued at $325,000 after purchasing an additional 6,266 shares during the last quarter. Swiss National Bank raised its position in GoodRx by 4.1% in the fourth quarter. Swiss National Bank now owns 161,400 shares of the company's stock valued at $751,000 after purchasing an additional 6,400 shares during the period. Fortem Financial Group LLC lifted its stake in GoodRx by 7.2% during the fourth quarter. Fortem Financial Group LLC now owns 119,179 shares of the company's stock worth $554,000 after purchasing an additional 7,996 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new position in shares of GoodRx during the third quarter worth $73,000. 63.77% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. KeyCorp cut their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Citigroup reduced their price target on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Wells Fargo & Company dropped their price objective on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Truist Financial reduced their target price on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $7.93.

GoodRx Stock Up 0.9 %

GDRX stock traded up $0.04 during trading on Friday, hitting $4.49. 545,787 shares of the company's stock were exchanged, compared to its average volume of 1,381,942. The stock has a market capitalization of $1.72 billion, a price-to-earnings ratio of -149.67, a PEG ratio of 2.46 and a beta of 1.25. GoodRx Holdings, Inc. has a 52-week low of $3.82 and a 52-week high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The business has a 50-day moving average price of $4.62 and a two-hundred day moving average price of $4.97.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.